Manufacturing roundup: Activist investor reportedly takes stake in Catalent; ProKidney caps off purchase of NC manufacturing site

The activist shareholder Elliott Investment Management has built a stake in the contract manufacturer Catalent, according to a report from The Wall Street Journal.

The Journal said Wednesday that Elliott may be wanting to make a “shake-up” on the board of Catalent. Those familiar with the matter told the WSJ that Elliott has been speaking to director candidates about joining nominees to run in a proxy content.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Botulinum battle heats up with FDA approving Daxxify for cervical dystonia – Pharmaceutical Technology

As per Revance, Daxxify should be available at the beginning of 2024. Image credit: Shutterstock/Elnur. Revance Therapeutics has entered the cervical dystonia treatment arena after

August 14, 2023

Is the US Preparing for Another Pandemic? This Stock Could Hold the Answer

Smallpox is one of the deadliest diseases known to humankind. It killed more than 300 million people in the 20th century alone, possessing a 30% mortality rate

July 19, 2024

Using machine learning to identify key predictors of mortality in dementia patients

Researchers at the Icahn School of Medicine at Mount Sinai and others have harnessed the power of machine learning to identify key predictors of mortality

February 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.